{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:32:50Z","timestamp":1785807170316,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI22\/01660"],"award-info":[{"award-number":["FIS PI22\/01660"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01298-6","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:58:06Z","timestamp":1747223886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations"],"prefix":"10.1038","volume":"15","author":[{"given":"Carlos","family":"Jimenez-Vicente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Cardus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-4665","authenticated-orcid":false,"given":"Sandra","family":"Casta\u00f1o-Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0287-6967","authenticated-orcid":false,"given":"Guillermo","family":"Ramil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garcia-Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gomez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8897-3170","authenticated-orcid":false,"given":"Daniel","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Lucia","family":"Sturla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lopez-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-5356","authenticated-orcid":false,"given":"Alexandra","family":"Martinez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Cortes-Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Isabel","family":"Perez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7666-5055","authenticated-orcid":false,"given":"Ines","family":"Zugasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Carcelero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Vall-Llovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Nomdedeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2180-2371","authenticated-orcid":false,"given":"Guadalupe","family":"O\u00f1ate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pratcorona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-0929","authenticated-orcid":false,"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Diaz-Beya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Spanish CETLAM Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"1298_CR1","doi-asserted-by":"crossref","unstructured":"Short NJ, Dillon R. Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development. Am J Hematol. 2024. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/ajh.27482.","DOI":"10.1002\/ajh.27482"},{"key":"1298_CR2","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:1890\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4600.","journal-title":"JAMA Oncol"},{"key":"1298_CR3","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"1298_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood-2022-158518","volume":"140","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat VA, Thirman MJ, Garcia JS, Fiedler W, et al. Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy. Blood. 2022;140:529\u201331. https:\/\/doi.org\/10.1182\/blood-2022-158518.","journal-title":"Blood"},{"key":"1298_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, et al. Measurable Residual Disease Response and Prognosis in Treatment-Na\u00efve Acute Myeloid Leukemia with Venetoclax and Azacitidine. J Clin Oncol. 2022;40:855\u201365.","journal-title":"J Clin Oncol"},{"key":"1298_CR6","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","volume":"5","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021;5:1876\u201383.","journal-title":"Blood Adv"},{"key":"1298_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/blood.2023021579","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Tiong IS, O\u2019Nions J, Dennis M, Mokretar K, Ivey A, et al. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. Blood. 2024;143:336\u201341. https:\/\/doi.org\/10.1182\/blood.2023021579.","journal-title":"Blood"},{"key":"1298_CR8","unstructured":"Arber D, Wang S, Branford S, Foucar K, Gotlib J, Hobbs G, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. Blood. 2022; Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2022015850\/1905221\/blood.2022015850.pdf."},{"key":"1298_CR9","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"1298_CR10","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2022016867\/1906555\/blood.2022016867.pdf.","DOI":"10.1182\/blood.2022016867"},{"key":"1298_CR11","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Available from: http:\/\/ashpublications.org\/blood\/articlepdf\/doi\/10.1182\/blood.2024025409\/2239875\/blood.2024025409.pdf.","DOI":"10.1182\/blood.2024025409"},{"key":"1298_CR12","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/ajh.27087","volume":"98","author":"F Ravandi","year":"2023","unstructured":"Ravandi F, Cloos J, Buccisano F, Dillon R, D\u00f6hner K, Freeman SD, et al. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. Am J Hematol. 2023;98:1847\u201355. https:\/\/doi.org\/10.1002\/ajh.27087.","journal-title":"Am J Hematol"},{"key":"1298_CR13","doi-asserted-by":"publisher","unstructured":"Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA. 2023;329:745\u201355. Available from: https:\/\/doi.org\/10.1001\/jama.2023.1363.","DOI":"10.1001\/jama.2023.1363"},{"key":"1298_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703\u201313. https:\/\/doi.org\/10.1182\/blood-2018-02-829911.","journal-title":"Blood"},{"key":"1298_CR15","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Vicente C, Arribas I, Pomares H, Ramil G, Casta\u00f1o-Diez S, P\u00e9rez-Valencia AI, et al. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. Haematologica. 2025; Available from: https:\/\/haematologica.org\/article\/view\/11910.","DOI":"10.3324\/haematol.2024.286589"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01298-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:58:11Z","timestamp":1747223891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01298-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01298-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CJV serves as educational speaker for AbbVie and Pfizer and received travel grants from AbbVie, Jazz Pharmaceuticals and Pfizer. SV received travel, accommodations, and expenses from Astellas Pharma, Pfizer, Servier, AbbVie, and Jazz Pharmaceuticals; serves as consultant or in an advisory role (without honoraria) for Astellas Pharma, Pfizer, Servier, AbbVie, and Jazz Pharmaceuticals FG serves as educational speaker for AbbVie. AMR serves as a consultant or in an advisory role, for Bristol Myers Squibb (BMS), AbbVie, and Kite Gilead; received travel grants from Kite Gilead, Roche, Takeda, Janssen, and AbbVie; and serves as a speaker for AbbVie and Gilead. MDB serves as a consultant for, in an advisory role for, received travel grants from, or served as speaker for BMS, AbbVie, Astellas, JazzPharma, Takeda, and Novartis. JE declares consultancy honoraria from AbbVie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, and Daichii-Sankyo, and received research grants from Novartis, Jazz Pharmaceuticals, and Pfizer. The remaining authors declare no competing financial interests. The founders had no role in the design of the study; in the collection, analyses or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of the Hospital Cl\u00ednic de Barcelona and conducted following standards set forth by the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided their informed consent for the use of laboratory results and genetic analyses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"94"}}